JUN 1 0 2003

K031569

Attachment D

SUMMARY OF SAFETY AND EFFECTIVENESS
FOR
DATASCOPE'S CA 40 8Fr. Intra-Aortic Balloon Catheters
Prepared in accordance with 21 CFR Part 807.92)

A. GENERAL INFORMATION

Submitter:	Datascope Corp. Cardiac Assist Division
Address	15 Law Drive Fairfield, NJ 07004
Contact Person:	JoAnn Taylor Global Regulatory Affairs Specialist

B. DEVICE INFORMATION

Generic Name:	Intra-Aortic Balloon Catheter (IAB)
Trade Name:	Datascope's 8 Fr. Intra-Aortic Balloon Catheter (IAB)
Classification Name:	Intra-Aortic Balloon Catheters (IAB) are classified under 21 CFR 870.3535

C. PREDICATE DEVICE INFORMATION

Datascope's CA 40 Intra-Aortic Balloon Catheters (IAB) are substantially equivalent to the following marketed devices:

- K013326, Datascope Fidelity 8Fr. Alt B Intra-Aortic Balloon Catheters (S/E 11/02/01).
- K003598, Datascope Profile 8Fr. Intra-Aortic Balloon Catheters w/Alt B and Gas Lumen Insert (S/E 12/21/00)

D. DEVICE DESCRIPTION/INTENDED USE

The intra-aortic balloon is placed in the descending aorta just below the subclavian artery and is intended to improve cardiovascular functioning during the following situations:

- Refractory unstable angina
- Impending infarction
- Acute MI
- Refractory ventricular failure
- Complications of acute MI (i.e. Acute MR or VSD, or papillary muscle rupture)
- Cardiogenic shock
- Support for diagnostic, percutaneous revascularization, and interventional procedures.
- Ischemia related intractable ventricular arrhythmias
- Septic shock
- Intraoperative pulsatile flow generation
- Weaning from bypass
- Cardiac support for non-cardiac surgery
- Prophylactic support in preparation for cardiac surgery
- Post surgical myocardial dysfunction/low cardiac output syndrome
- Myocardial contusion
- Mechanical bridge to other assist devices
- Cardiac support following correction of anatomical defects

E. TECHNOLOGICAL CHARACTERISTICS

Datascope's CA 40 8Fr. IAB Catheters are substantially equivalent to the predicate devices with regard to intended use.

Modifications to Datascope's predicate 8 Fr. IAB catheters include a material modification of Datascope's currently marketed balloon membrane to enable the balloon to be manufactured using different molding process. The catheter tip material is that of a previously FDA cleared IAB tip material and the catheter's tip dimension has been tapered.

These modifications to the 8Fr. IAB catheters have been demonstrated not to affect safety or efficacy of the device.

F. NON-CLINICAL TESTS

The results of in-vitro tests conducted demonstrate that the functionality and performance characteristics of the device are comparable to the currently marketed devices.

G. CLINICAL TESTS

There have been no clinical evaluations of the new device.

H. CONCLUSIONS

Based on the information presented in this 510(k) premarket notification, Datascope's CA 40 8 Fr. IAB Catheters are considered substantially equivalent to Datascope's currently marketed IABs.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

JUN 10 2003

Datascope Corporation
Cardiac Assist Division
c/o Ms. JoAnn Taylor
Global Regulatory Affairs Specialist
15 Law Drive
Fairfield, NJ 07004

Re: K031569
8Fr. Intra-Aortic Balloon Catheter
Regulation Number: 21 CFR 870.3535
Regulation Name: Intra-Aortic Balloon Catheter
Regulatory Class: Class III (three)
Product Code: DSP
Dated: May 19, 2003
Received: May 20, 2003

Dear Ms. Taylor:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,



Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Attachment B

Indications for Use Statement

510(k) Number K031569

Device Name Datascope's CA 40 8Fr. Intra-Aortic Balloon Catheters

Indications for Use Datascope's CA 40 8Fr. Intra-Aortic Balloon Catheters have the following indications for use:

- Refractory unstable angina
- Impending infarction
- Acute MI
- Refractory ventricular failure
- Complications of acute MI (i.e. Acute MR or VSD, or papillary muscle rupture)
- Cardiogenic shock
- Support for diagnostic, percutaneous revascularization, and interventional procedures.
- Ischemia related intractable ventricular arrhythmias
- Septic shock
- Intraoperative pulsatile flow generation
- Weaning from bypass
- Cardiac support for non-cardiac surgery
- Prophylactic support in preparation for cardiac surgery
- Post surgical myocardial dysfunction/low cardiac output syndrome
- Myocardial contusion
- Mechanical bridge to other assist devices
- Cardiac support following correction of anatomical defects

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CCRH, Office of Device Evaluation (ODE)

Prescription Use X
(Per 21 CFR 801.109)

(Division Sign-Off)
Division of Cardiovascular Devices

Over-The-Counter Use _____

510(k) Number K031569